Comparative Molecular Field Analysis and Comparative Molecular Similarity Indices Analysis of Thalidomide Analogues as Angiogenesis Inhibitors

Journal of Medicinal Chemistry

Volumn 47, Issue 9, 2004, Pages 2219-2227

  Lepper, Erin R ^a   Ng, Sylvia S W ^a   Gütschow, Michael ^b   Weiss, Michael ^c   Hauschildt, Sunna ^d   Hecker, Thomas K ^d   Luzzio, Frederick A ^e   Eger, Kurt ^d   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF BONN   (Germany)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; THALIDOMIDE DERIVATIVE;

ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; CONTROLLED STUDY; DRUG ACTIVE SITE; DRUG ACTIVITY; DRUG CONFORMATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; MICROVASCULATURE; MOLECULAR MODEL; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; SOLID TUMOR; VALIDATION PROCESS; VASCULAR RING;

ANGIOGENESIS INHIBITORS; ANIMALS; AORTA, THORACIC; MALE; MICROCIRCULATION; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUSCLE, SMOOTH, VASCULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; RATS, SPRAGUE-DAWLEY; THALIDOMIDE;

EID: 1842628789     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0304820     Document Type: Article

References (23)

1. Folkman, J. Tumor angiogenesis: a possible control point in tumor growth. Ann. Intern. Med. 1975, 82, 96-100.
2. Kim, K. J.; Li, B.; Winer, J.; Armanini, M.; Gillett, N. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362, 841-844.
3. Singhal, S.; Mehta, J. Thalidomide in cancer: potential uses and limitations. BioDrugs 2001, 15, 163-172.
4. Dredge, K.; Dalgleish, A. G.; Marriott, J. B. Thalidomide analogues as emerging anti-cancer drugs. Anticancer Drugs 2003, 14, 331-335.
5. Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 1999, 341, 1565-1571.
6. Little, R. F.; Wyvill, K. M.; Pluda, J. M.; Welles, L.; Marshall, V. et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 2000, 18, 2593-2602.
7. Fine, H. A.; Figg, W. D.; Jaeckle, K.; Wen, P. Y.; Kyritsis, A. P. et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol. 2000, 18, 708-715.
8. Eisen, T.; Boshoff, C.; Mak, I.; Sapunar, F.; Vaughan, M. M. et al. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br. J. Cancer 2000, 82, 812-817.
9. Figg, W. D.; Dahut, W.; Duray, P.; Hamilton, M.; Tompkins, A. et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res. 2001, 7, 1888-1893.
10. Bauer, K. S.; Dixon, S. C.; Figg, W. D. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol. 1998, 55, 1827-1834.
11. Ando, Y.; Fuse, E.; Figg, W. D. Thalidomide metabolism by the CYP2C subfamily. Clin. Cancer Res. 2002, 8, 1964-1973.
12. Eriksson, T.; Bjorkman, S.; Roth, B.; Bjork, H.; Hoglund, P. Hydroxylated metabolites of thalidomide: formation in-vitro and in-vivo in man. J. Pharm. Pharmacol. 1998, 50, 1409-1416.
13. Schumacher, H.; Smith, R. L.; Williams, R. T. The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br. J. Pharmacol. 1965, 25, 324-337.
14. Eriksson, T.; Bjorkman, S.; Hoglund, P. Clinical pharmacology of thalidomide. Eur. J. Clin. Pharmacol. 2001, 57, 365-376.
15. Hoglund, P.; Eriksson, T.; Bjorkman, S. A double-blind study of the sedative effects of the thalidomide enantiomers in humans. J. Pharmacokinet. Biopharm. 1998, 26, 363-383.
16. Kenyon, B. M.; Browne, F.; D'Amato, R. J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. 1997, 64, 971-978.
17. Knoche, B.; Blaschke, G. Investigations on the in-vitro racemization of thalidomide by high-performance liquid-chromatography. J. Chromatog. A 1994, 666, 235-240.
18. Cramer, R.; Patterson, D.; Bunce, J. Comparative Molecular-Field Analysis (CoMFA) 1. Effect of Shape on Binding of Steroids to Carrier Proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
19. Wold, S.; Ruhe, A.; Wold, H.; Dunn, W. J. The collinearity problem in linear regression - The partial least-squares (PLS) approach to generalized inverses. Siam J. Sci. Stat. Comput. 1984, 5, 735-743.
20. Bush, B. L.; Nachbar, R. B. Sample-distance Partial Least-Squares PLS Optimized for Many Variables, with Application to CoMFA. J. Comput.-Aided Mol. Des. 1993, 7, 587-619.
21. Clark, R. D.; Sprous, D. G.; Leonard, J. M. Validating models based on large data sets. Rational Approaches to Drug Design; Prous Science SA: Barcelona, 2001; pp 475-485.
22. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 1994, 37, 4130-4146.
23. Macpherson, G. R. Unpublished results.